Last updated on April 17, 2014 at 17:30 EDT

Eaton Apothecary Selects Predictive Acquisition Cost (PAC) Drug Price Type

June 27, 2012

TAMPA, Florida, June 28, 2012 /PRNewswire/ –

Holliston, Mass.-based pharmacy chain selects PAC from Elsevier / Gold

Standard and Glass Box Analytics

Leading drug information provider, Elsevier / Gold Standard
[http://www.goldstandard.com ], announced today that Holliston, Mass.-based pharmacy chain
Eaton Apothecary [http://www.eatonapothecary.com/index.php ] has purchased the new
Predictive Acquisition Cost (PAC), developed by Glass Box Analytics
[http://www.glassboxanalytics.com ] and exclusively sold by Elsevier / Gold Standard.

Introduced earlier this year, PAC is a new drug price type that more closely tracks
true acquisition cost. PAC employs predictive analytics techniques to estimate acquisition
cost considering various factors, including MAC benchmarks, published price lists,
existing price benchmarks, drug dispensing metrics, supply-demand measures, and
survey-based acquisition costs. Independent tests show that PAC tracks drug acquisition
cost with sufficient accuracy to support pricing activity.

“Glass Box Analytics has done an exceptional job developing the new price type, PAC,”
said Eaton Apothecary Vice President of Operating Policy John H. Lynch, III. “We are eager
to begin using PAC for our company and look forward to the growth potential the new tool
will offer as we integrate its intelligence into our existing systems.”

Eaton Apothecary has 16 locations, including traditional retail pharmacies and those
focused on home delivery and specialized care. As a classic community-centered pharmacy,
Eaton Apothecary prides itself for its commendable one-on-one service with patients. With
a reputation in the industry as an early-adopter of new, enhanced technologies and
marketplace trends, Eaton Apothecary selected PAC, adding to the company’s competitive

“We are excited to be working with Eaton Apothecary as they begin to implement PAC
into their systems,” said Marianne Messer, Elsevier / Gold Standard President. “We have
confidence that PAC meets the industry need for a drug price type that is a close
indicator of true acquisition cost, and is accurate, transparent, comprehensive and

Eaton Apothecary plans to utilize PAC for reimbursement analysis, wholesaler request
for proposal processes with standards for deviations from the PAC price type, and as a
cash pricing base.

Elsevier / Gold Standard

Based in Tampa, FL, Elsevier / Gold Standard uses innovative technologies to provide a
complete suite of drug information and decision support solutions. With a tenacious
commitment to product quality, Elsevier / Gold Standard solutions empower healthcare
organizations, professionals and consumers to meet the most pressing healthcare
challenges, improve patient safety and ensure optimal outcomes. To learn more about
Elsevier / Gold Standard, visit http://www.goldstandard.com.

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information
products and services. The company works in partnership with the global science and health
communities to publish more than 2,000 journals, including The Lancet
[http://www.thelancet.com ] and Cell [http://www.cell.com ], and close to 20,000 book
titles, including major reference works from Mosby and Saunders. Elsevier’s online
solutions include ScienceDirect [http://www.sciencedirect.com ], Scopus
[http://www.scopus.com ], Reaxys [http://www.reaxys.com ], MD Consult
[http://www.mdconsult.com ] and Mosby’s Nursing Suite [http://www.confidenceconnected.com
], which enhance the productivity of science and health professionals, and the SciVal
suite [http://www.scival.com ] and MEDai’s Pinpoint Review [http://www.medai.com ], which
help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier [http://www.elsevier.com ]
employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC
[http://www.reedelsevier.com ], a world-leading publisher and information provider, which
is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN
(Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

        Media contact
        Tom Reller
        Vice President, Global Corporate Relations, Elsevier

SOURCE Elsevier

Source: PR Newswire